MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

65.68 -1.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

65.52

Max

67.14

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.2M

-49M

Verkäufe

-9.1M

33M

EPS

-0.81

Gewinnspanne

-151.352

Angestellte

283

EBITDA

-9.5M

-47M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+24.66% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

92M

4.2B

Vorheriger Eröffnungskurs

67.06

Vorheriger Schlusskurs

65.68

Nachrichtenstimmung

By Acuity

50%

50%

157 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Juli 2025, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3. Juli 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3. Juli 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3. Juli 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Juli 2025, 23:15 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3. Juli 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3. Juli 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3. Juli 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3. Juli 2025, 22:21 UTC

Ergebnisse

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3. Juli 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Juli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3. Juli 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3. Juli 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Juli 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3. Juli 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3. Juli 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3. Juli 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3. Juli 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Juli 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3. Juli 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3. Juli 2025, 16:55 UTC

Ergebnisse

Travel Stocks Could Offer Investors a Glorious -2-

3. Juli 2025, 16:55 UTC

Ergebnisse

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3. Juli 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3. Juli 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Juli 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Juli 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3. Juli 2025, 15:47 UTC

Ergebnisse

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3. Juli 2025, 15:36 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

24.66% Vorteil

12-Monats-Prognose

Durchschnitt 83.42 USD  24.66%

Hoch 94 USD

Tief 72 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

12

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

157 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.